An Examination of the Ethical, Legal and Social Implications of the WTO TRIPS Agreement on access to gene and cell-based treatments including CAR T and CRISPR

8-10 October 2019

Brocher Foundation
Route d’Hermance 471
1248 Hermance
Switzerland

List of participants

1) Name: Marco Aleman
   **Title and Affiliation:** Director, Patent Law Division, World Intellectual Property Organization (WIPO)
   **Location:** Geneva, Switzerland

   **Biography:** Marco Aleman is Director of the Patent Law Division of the World Intellectual Property Organization (WIPO). Prior to joining WIPO in 1999, Mr. Aleman was a research fellow at the Max Planck Institute in Munich, Germany. From 1995 to 1998, Mr. Aleman was Director of the Colombian Industrial Property Office.

2) Name: Gregg Alton
   **Title and Affiliation:** Chief Patient Officer, Gilead Sciences
   **Location:** San Francisco, California, United States of America

   **Biography:** Mr. Alton leads Gilead’s patient outreach and engagement initiatives and the company’s efforts to facilitate access to its medicines around the world. He oversees the corporate and medical affairs functions and developing world access programs, as well as its digital patient solutions and patient-centered outcomes groups and commercial operations in certain countries.

   Since joining Gilead in 1999, Mr. Alton has held a number of positions at the company with experience in legal, medical affairs, policy and commercial. He previously served as general counsel.

   Mr. Alton is a member of the Board of Directors of the AIDS Institute, the Boys and Girls Clubs of Oakland, and the Partners in Health Board of Trustees. He serves on the U.S. government’s Industry Trade Advisory Committee on Intellectual Property Rights and the advisory boards for UCSF Global Health Group, USC Schaeffer Center for Health Policy and
Economics and the UC Berkeley College of Letters & Science. He is also a member of the Board of Directors of Collidion, Inc.

Mr. Alton received a bachelor’s degree in legal studies from the University of California at Berkeley and a law degree from Stanford University.

3) **Name:** Thiru Balasubramaniam  
**Title and affiliation:** Managing Director, KEI Europe  
**Location:** Geneva, Switzerland

**Biography:** Thiru Balasubramaniam is the Managing Director for KEI Europe. Mr. Balasubramaniam has represented KEI Europe at the European Parliament, the European Commission, and the EU Alliance for Responsible R&D and Affordable Medicines. In his role as Geneva representative for Knowledge Ecology International (KEI), Mr. Balasubramaniam has represented KEI in various multilateral fora including the Marrakesh Diplomatic Conference to Conclude a Treaty to Facilitate Access to Published Works by Visually Impaired Persons and Persons with Print Disabilities, the World Intellectual Property Organization (WIPO), the Internet Governance Forum, the World Health Organization (WHO) and the World Trade Organization (WTO).

Prior to his post, Thiru worked at Health Action International (HAI) in Colombo and at the WHO in Geneva as a technical officer in the Department of Essential Drugs and Medicines Policy, dealing with access to medicines and intellectual property.

4) **Name:** Hannes Braberg  
**Title and affiliation:** Senior Staff Scientist, University of California, San Francisco  
**Location:** San Francisco, California, United States of America

**Biography:** Dr. Braberg is a senior staff scientist at the University of California, San Francisco. He is an expert in network biology and genetics, and his work focuses on the design of high-throughput biology platforms and analysis of large-scale genetics datasets. Hannes holds a Master’s in Biotechnology Engineering from Uppsala University and a PhD in Biophysics from the University of California, San Francisco.

5) **Name:** Jessica Burry  
**Title and affiliation:** HIV/HCV Pharmacist & HCV Lead, Médecins Sans Frontières (MSF) Access Campaign  
**Location:** Geneva, Switzerland

**Biography:** Jessica Burry comes from Newfoundland, Canada and graduated from the MUN School of Pharmacy in 2006, followed by a residency in clinical pharmacy at The Ottawa Hospital and MSc in Infectious Diseases from LSHTM. Jessica has experience in clinical & community pharmacy in Canada, clinical trials in tuberculosis, academia -teaching pharmacy technicians in Qatar, assessment of quality of medicines for UNICEF, and field experience with MSF (Médecins Sans Frontières – Doctors Without Borders) in Swaziland and DRC. Jessica joined the MSF Access Campaign, based in Geneva, Switzerland in 2015.
working on access to medicines issues related to HIV and Hepatitis C. Jessica is passionate about improving access to medicines for patients around the world, tackling issues related to R&D delays in pediatrics, quality of medicines and intellectual property.

6) **Name:** Ben Cashdan  
**Title and affiliation:** Economist and Filmmaker  
**Location:** Johannesburg, South Africa

**Biography:** Ben Cashdan is an economist and filmmaker based in Johannesburg.

From 1995 to 1996 Ben worked as an Economic Advisor in the Presidency of Nelson Mandela. Ben also worked for the UK Department for International Development.

Since 2000 Ben has focused on media work, producing a number of documentaries on global struggles for social justice. He was Executive Producer of a series of BBC World Debates on human rights in Africa. He now produces “the Big Debate”, the top Town Hall debate show in South Africa.

Ben is now working on a documentary on access to medicines entitled "A Fair Price for my Life".

7) **Name:** Julian Cockbain  
**Title and affiliation:** European Patent Attorney, Bioethics Institute Gent, Universiteit Gent  
**Location:** Ghent, Belgium

**Biography:** Dr Julian Cockbain is a Consultant European Patent Attorney based in Gent, Belgium and Oxford, UK. After taking a degree and a doctorate in chemistry at Oxford University, he joined the patent and trademark attorney firm Dehns in London in 1979, qualifying as a UK patent attorney in 1983 and as a European Patent Attorney in 1984. He was appointed partner at Dehns in 1985, a position he held until becoming a consultant in 2012. He has written and prosecuted several hundred patent applications and has published widely on patent-related matters. His publications include a book on exclusions from patentability in Europe (Cambridge University Press, 2012).

8) **Name:** Emer Cooke  
**Title and affiliation:** Director, Regulation of Medicines and other Health Technologies, World Health Organization  
**Location:** Geneva, Switzerland

**Biography:** In November 2016 Emer Cooke was appointed as Head of Regulation of Medicines and other Health Technologies with the World Health Organization (WHO) in Geneva. In this role, Ms Cooke is responsible for leading WHO’s global work on regulation of health technologies (medicines, vaccines, diagnostics, vector control products and devices), coordinating the regulatory teams (Norms and Standards, Prequalification, Regulatory Systems Strengthening), and working with member states and international partners to assure the quality, safety and efficacy of appropriate health technologies. Ms Emer Cooke
obtained her degree in pharmacy from Trinity College, Dublin in Ireland. She has additional Masters degrees in Science and in Business Administration, also from Trinity. During the period from 1985 to 1988 she worked in a number of positions within the Irish pharmaceutical industry before moving to the Irish drug regulatory authority as a pharmaceutical assessor in 1988. In 1991 she joined EFPIA, the European pharmaceutical industry association as Manager of Scientific and Regulatory Affairs in Brussels. From September 1998 to July 2002, she worked in the Pharmaceuticals unit of the European Commission, following which she was appointed as Head of Sector for Inspection at the European Medicines Agency (EMA) in London. Towards the end of 2008, Emer took on the newly created post of International Liaison Officer. She became Head of International Affairs in the context of EMA’s reorganization and remained in this position until November 2016.

9) Name: Erika Dueñas  
Title and affiliation: Technical Officer, Department of Essential Medicines and Health Products, World Health Organization  
Location: Geneva, Switzerland  
Erika Dueñas works at WHO HQ/Essential Medicines and Health Products department providing technical advice on the interfaces between public health, innovation and Intellectual Property (IP). She previously worked at the Medicines Patent Pool and has more than 20 years of experience in the field of access to medicines, innovation and IP. As a career diplomat, she worked many years for the Bolivian government, participating in international negotiations related to IP at the Andean Community, WHO, WTO, and WIPO. After her diplomatic mission at the Embassy in Washington as Chargée d’Affaires, she was Vice-Minister at the Ministry of Foreign Affairs in Bolivia. Erika holds a Master’s degree in International Law and Economics (LLM) from the World Trade Institute / Universities of Bern, Fribourg & Neuchâtel – Bern, Switzerland.

10) Name: Paul Fehlner  
Title and affiliation: Senior Vice President, Chief Intellectual Property Officer, Axcella Health, Former Head of Intellectual Property for Novartis Pharma  
Location: Cambridge, Massachusetts, United States of America  

Biography: Dr. Fehlner leads Axcella’s Intellectual Property and product exclusivity strategy. Prior to assuming this role, Dr. Fehlner was a Principal of Life Sciences Innovation LLC, a consulting company he founded in 2017 to advise on complex IP business strategy for products and technologies in life sciences, develop capabilities of legal and IP professionals, and provide BD&L support for research institutes, companies, and investors. He has been named to the IAM Strategy 300 World’s Leading Patent Professionals for the past four years.

Previously, Dr. Fehlner spent nine years as the Head of Intellectual Property for Novartis Pharma in Basel, Switzerland. In this role, he led a team responsible for obtaining, maintaining, and enforcing IP rights. The team created holistic portfolios of patents, trademarks, regulatory exclusivities, and reputation for Novartis products.

Dr. Fehlner joined Novartis in 2008 from Baker Botts, where he was a partner specializing in IP counselling and strategic planning in the pharmaceutical, biotechnology and medical
device industries, as well as litigation. Prior to that he was an associate and partner at Darby & Darby, with earlier experience as Biotechnology Counsel for Rhône-Poulenc Rorer and as an associate for boutique IP firm Klauber & Jackson. Dr. Fehlner started his career in 1990 as a law clerk in the biotech and pharmaceutical group at Pennie & Edmonds. In addition to life sciences, Dr. Fehlner has worked on chemical and material sciences technologies. Dr. Fehlner has a JD from Fordham University School of Law, a PhD in immunology and biochemistry from Rockefeller University (Lois P Markey Fellow), and a BS in chemistry from Haverford College (high honors; Phi Beta Kappa).

11) **Name:** Paolo Foggi  
**Title and affiliation:** Head of Innovation and Pharmaceutical Strategy Division, Italian Medicines Agency (AIFA)  
**Location:** Rome, Italy

**Biography:** Paolo Foggi, MD, is board certified Medical Oncologist. He is Head of Innovation and Pharmaceutical Strategy Division at Italian Medicines Agency (AIFA).

He joined the “Regina Elena” National Cancer Institute in 1996 as a clinical research fellow, and he then served there as medical oncologist involved in clinical research activities, mainly in the field of breast cancer, until 2010.

He joined AIFA in April 2010, serving as clinical assessor in Research and Clinical Trial Office; since April 2011 he was appointed Coordinator of AIFA activities on anticancer drugs, including clinical assessment in the pricing and reimbursement evaluation procedures at national level as well in centralised procedures, support in the planning, design and analysis of Anticancer Drug Registries, evaluation of requests for the inclusion of new anticancer drugs in the early access to medicine national scheme, and participation in national scientific advice activities.

Currently he is Head of Innovation and Pharmaceutical Strategy Division at AIFA.

He is vice-chair of the EMA Oncology Working Party and member of the EMA Scientific Advice Working Party.

12) **Name:** Charles Gore  
**Title and affiliation:** Executive Director, Medicines Patent Pool (MPP)  
**Location:** Geneva, Switzerland

**Biography:** Charles Gore is the Executive Director of the Medicines Patent Pool. He took up the post in July 2018 following a career in patient representation and public health advocacy. He was diagnosed with hepatitis C in 1995 and cirrhosis in 1998. In 2000 he set up The Hepatitis C Trust in the UK which he ran for 18 years. In 2002 he was treated and cured of the virus. He helped create the European Liver Patients Association and was its first President in 2004. In 2007 he organised a meeting of hepatitis patient organisations from around the world to agree on co-ordinated global action. From this emerged the decision to hold an annual World Hepatitis Day and to create a new NGO, the World Hepatitis Alliance, of which Charles was the President from 2007 until the end of 2017. As a result of advocacy
by the Alliance and its members, the World Health Organization (WHO) adopted successive
viral hepatitis resolutions in 2010, 2014 and 2016, making World Hepatitis Day an official
day, celebrated on 28 July every year, and endorsing the first Global Health Sector Strategy
on viral hepatitis with the goal of eliminating hepatitis B and C by 2030.

In addition to direct advocacy with over 50 Ministries of Health, Charles has led on advising
countries on finding sustainable domestic financing for hepatitis programmes, including
health system elements such as infection control and blood and injection safety. Charles
also sits on a number of national and international advisory bodies, including the WHO
Director-General’s Strategic and Technical Advisory Committee for Viral Hepatitis and has
been a member of all the WHO guideline development groups on testing and treating viral
hepatitis.

13) Name: Simone Hammersley
**Title and affiliation:** Health scientist and filmmaker
**Location:** Johannesburg, South Africa

**Biography:** Simone Hammersley has an honours degree in Medical Biosciences from the
University of the Western cape. She worked as a researcher at the Council for Scientific and
Industrial Research in South Africa, specialising in development of protocols for diagnosis of
communicable diseases in the field in less developed countries.

Since 2017 Simone has been working in the media, including contributing to a youth TV
series on race, class, gender and human rights in South Africa.

In 2019 Simone started work on a global documentary on access to medicines.

14) Name: Tim Hubbard
**Title and affiliation:** Head of Department of Medical & Molecular Genetics, Professor of
Bioinformatics, King’s College
**Location:** London, United Kingdom

**Biography:** Dr. Tim Hubbard studied Biochemistry at the University of Cambridge, followed
by a PhD in Protein Design at the Department of Crystallography, Birkbeck College,
University of London. Following a postdoctoral fellowship at the Protein Engineering
Research Institute in Osaka under the EU scientific training program in Japan, he returned to
Cambridge in 1990 as a Zeneca Fellow at the MRC Centre for Protein Engineering to work
on protein folding, classification and design.

He co-founded SCOP (the Structural Classification of Proteins database) and developed
algorithms to make protein structure predictions and assess their accuracy and to calibrate
the reliability of sequence alignment methods. He was one of the most successful
participants in the first CASP (Critical Assessment of Structure Prediction) competition in
In 1997 he joined the Wellcome Trust Sanger Institute to become Head of Human Genome Analysis, where he was one of the organisers of the sequencing of the human genome. In 1999 he co-founded the Ensembl project to analysis, organise and provide access to the human genome. From 2007 he led the GENCODE project to annotate the structure of all human genes, initially as part of the ENCODE project. He was the Sanger Institute PI of the Genome Reference Consortium, which is responsible for reference genome sequences of human, mouse and zebrafish. He became Head of the Informatics division from 2007. After the announcement of the 100,000 genomes project 2012 he was seconded part-time as a specialist advisor for genomics to NHS England leading up to the creation of Genomics England.

In October 2013 Dr. Hubbard was appointed Professor of Bioinformatics and Head of the Department of Medical & Molecular Genetics at King’s College London and Director of Bioinformatics for King’s Health Partners with a part-time secondment as Head of Genome Analysis at Genomics England. In 2018 he was also appointed as Associate Director (King’s) for the Health Data Research London Site.

15) **Name:** Roger Kampf  
**Title and affiliation:** Counsellor, Intellectual Property, Government Procurement and Competition Division, World Trade Organization (WTO)  
**Location:** Geneva, Switzerland

**Biography:** Roger Kampf is from Hamburg, Germany. He joined the World Trade Organization in May 2004 where he is responsible for the Secretariat's work in the area of TRIPS and public health and IP enforcement. He also oversees the Division's technical assistance activities in relation to intellectual property. From 2016 to 2018, Mr Kampf has been the Secretary of the Council for TRIPS.

From 1998 to 2004, Mr. Kampf worked for the European Commission at its headquarters in Brussels and at the permanent representation in Geneva, where he was responsible for intellectual property issues in WTO and WIPO, as well as for government procurement. Prior to this, he was involved in negotiations on financial services under the GATS Agreement, and also worked as an assistant in public law and European Communities law at the University of Hamburg.

Mr. Kampf holds a law degree from the University of Hamburg and a degree in public administration from the Ecole Nationale d'Administration in Paris. He has published on various aspects of EC and WTO law.

16) **Name:** Marie Paule Kieny  
**Title and affiliation:** Director of Research at Inserm (Institut national de la santé et de la recherche médicale)  
**Location:** Paris, France and Geneva, Switzerland
Biography: Dr Marie-Paule Kieny is currently Director of Research at Inserm (Institut national de la santé et de la recherche médicale) in Paris, where she assists the President on International Institutional Collaborations.

She is also the Chair of the Board of the Drugs for Neglected Diseases Initiative (DNDi, Geneva, Switzerland) and of the Medicines Patent Pool Foundation (MPPF, Geneva, Switzerland). She is also a member of the Board of the Human Vaccine Project (HVP, New York, USA) and a Non-Executive Independent Director of bioMérieux (Lyon, France).

Until June 2017, Dr Kieny served as the Assistant Director-General for Health Systems and Innovation at the World Health Organization. Dr Kieny also directed the WHO Initiative for Vaccine Research from 2001 to 2010. Key successes under her leadership roles at WHO include the development and licensing of new vaccines against bacterial meningitis, addressing global supply of pandemic influenza vaccine especially in developing countries through technology transfer and manufacturing, and vaccines against poverty-related diseases. Such initiatives are continuing priorities of Dr Kieny.

Before joining WHO, Dr Kieny held top research positions in the public and private sectors in France which included Assistant Scientific Director of Transgene S.A. from 1981 to 1988 and Director of Research and Head of the Hepatitis C Virus Molecular Virology Group at the Institute of Virology, (INSERM) from 1999 to 2000.

Dr Kieny received her PhD in Microbiology from the University of Montpelier (1980), where she was also awarded a University Diploma in Economics, and her Diplôme d’Habilitation à Diriger des Recherches from the University of Strasbourg in 1995. She has published over 350 articles and reviews, mainly in the areas of infectious diseases, immunology, vaccinology, and health systems.

Dr Kieny has been awarded the title of Chevalier dans l’Ordre National de la Légion d’honneur (Knight in the National Order of the Legion of Honour, France) in 2016, and of Chevalier de l’Ordre National du Mérite, au titre du Ministère de la Recherche (Knight of the National Order of Merit, under the Ministry of Research, France) in 2000. She was the recipient of the International Inserm Prize in 2017, the Génération 2000-Impact Médecin Prize in 1994, and of the Innovation Rhône-Poulenc Prize in 1991.

17) Name: Gaëlle Krikorian
Title and affiliation: Head of Policy, Médecins Sans Frontières (MSF) Access Campaign
Location: Paris, France

Biography: Dr Gaëlle Krikorian is Head of Policy at Médecins Sans Frontières’ (MSF) Access Campaign.

Prior to joining MSF, she was an advisor on Access to Knowledge and Intellectual Property issues for the Greens–European Free Alliance at the European Parliament. She has co-edited a book on social mobilizations in this field: Access to Knowledge in the Age of Intellectual Property.
Dr Krikorian has a PhD in sociology from École des Hautes Études en Sciences Sociales (EHESS) and is a member of the Interdisciplinary Research Institute on Social Issues (IRIS), Paris. She has conducted extensive research on social movements, globalization, health and technologies. She has authored several articles on issues concerning the Commons, intellectual property, access to medicines and access to knowledge. Her previous experience includes working for almost ten years as an HIV/AIDS activist with Act Up in Paris.

18) **Name:** Katherine Littler  
**Title and affiliation:** Senior Ethics Specialist and Co-lead  
**Location:** Geneva, Switzerland

**Biography:** In October 2018, Katherine Littler joined the Global Health Ethics Team at the World Health Organization in Geneva as Senior Ethics Specialist and Co-lead. Current areas of focus, include: emerging technologies, particularly human genome editing; genomics; human challenge studies; and epidemic preparedness and response. Prior to this, Katherine co-led the Global Policy Team at Wellcome. She has a background in medical law and ethics and during her time at Wellcome provided strategic advice on regulatory, governance and ethical issues. She led a programme of work focusing on research ethics, global governance and advocacy, epidemic preparedness, genomics and emerging technologies, and evidence into policy. She has sat on many oversight bodies, including: the PHE Ebola Governance Group; the IDDO Ebola Platform Steering Committee; the H3Africa Ethics and Regulatory Working Group and she was the chair of the GLOPID-R data sharing working group.

19) **Name:** Vanessa López  
**Title and affiliation:** Executive Director, Salud por Derecho  
**Location:** Madrid, Spain

**Biography:** Vanessa López is the co-founder and executive director of Salud por Derecho, a non-profit organization dedicated to globally defending the right to health based in Spain. She graduated in Social Psychology by Autonomous University of Madrid and received a master’s degree in International Development. In 2003, a group of activists decided to come together in order to get Spain and the rest of the world to stop looking the other way in the fight against AIDS in impoverished countries, those most affected by the disease. Today, Salud por Derecho creates campaigns, formulates proposals and advocates the defense of the right to health from the perspective of social justice and inequality and putting the focus on governments. As for the access to medicines, the organization aims to contribute to build an efficient and sustainable R&D system that ensures quality medicines that people need at affordable price. Salud por Derecho also leads a multi-stakeholder campaign in Spain called No Es Sano (It’s Not Healthy) to cure medicines innovation model.

20) **Name:** James Love  
**Title and affiliation:** Director, Knowledge Ecology International  
**Location:** Washington DC, United States of America
Biography: James Love is the Director of Knowledge Ecology International (KEI). Mr. Love is the author of a WIPO study on "Alternatives to the Patent System that are used to Support R&D Efforts," and the WHO/UNDP guidelines for "Remuneration Guidelines for Non-Voluntary Use of a Patent on Medical Technologies." He holds a graduate degree in public affairs from Princeton University and a masters in public administration from Harvard.

21) Name: Renato Massimi
Title and affiliation: Head of GMP inspectorate, Agenzia Italiana del Farmaco (Italian Medicines Agency)
Location: Rome, Italy

Biography: Dr Renato Massimi is the Head of the Manufacturing Authorizations Office at the Italian Medicines Agency (AIFA). In this role, he has managed manufacturing sites applications for finished products and managed GMP inspections’ follow up for finished products. Prior to joining AIFA in 2003, he served as chemist officer in the Italian Ministry of Health’s Medicines General Department in the Drug Manufacturing Office.

22) Name: Yannis Natsis
Title and affiliation: Policy Manager for Universal Access and Affordable Medicines, European Public Health Alliance (EPHA)
Location: Brussels, Belgium

Biography: Yannis Natsis currently leads the advocacy for better and affordable medicines at the European Public Health Alliance (EPHA). Before joining EPHA in January 2016, he worked at the European Parliament, the Greek Ministry of Foreign Affairs, the UN and the private sector in Brussels and Athens. Between 2013-2015, Yannis was Advocacy Advisor for the TransAtlantic Consumer Dialogue (TACD) focusing on access to medicines. Between 2006-2010, he was an investigative reporter for Greece’s award-winning TV news programme “Fakeli,” and a contributor to the Greek daily “Kathimerini”.

Yannis is a founding member of the European Alliance for Responsible R&D and Affordable Medicines and represents the public health voice on the following groups: High Level Group (HLG) to the Round Table meetings for European Health Ministers and Heads of Europe of pharmaceutical companies; Patient and Consumer Working Party (PCWP) of the European Medicines Agency (EMA); Health Technology Assessment (HTA) Network Stakeholder Pool of the European Commission.

He has a Master’s degree in International Conflict Analysis from the University of Kent, UK and a Bachelor’s degree in European Studies from Panton University of Social and Political Sciences. A Greek national, he is fluent in Greek, English and French.

Yannis is committed to promoting transparency, accountability and protecting the public interest in health policy. He contributes to the discussions on regulatory developments in pharmaceuticals, medical innovation and patients’ access to treatment.
In May 2019, Yannis was appointed to the Management Board of the European Medicines Agency (EMA) by EU Member States. He is one of the two patient representatives on the Board with a 3-year mandate starting in June 2019. Since January 2018, he has been a member of the Board of the European Health Forum Gastein (EHFG) too.

23) **Name:** Valérie Paris  
**Title and affiliation:** Senior Health Policy Analyst, Organisation for Economic Cooperation and Development (OECD)  
**Location:** Paris, France

**Biography:** Valérie Paris joined the OECD Secretariat in September 2005 to contribute to the work undertaken by the Health Division. Since then, she has contributed to several projects on health systems’ characteristics and performance, providers’ payments, pharmaceutical policies and regional variations in health care use. She co-ordinated and co-authored the OECD reports *New Health Technologies - Managing Access, Value and Sustainability* (2017) and *Pharmaceutical Innovation and Access to Medicines* (2018). She is responsible for most OECD projects related to pharmaceuticals and medical devices. Previously, she was researcher at the French Institute of Research and Information on Health Economics (IRDES), a non-for-profit organization. She participated in research projects on pharmaceutical policies, physicians’ payment schemes, health accounts and comparative analysis of health systems.

She holds a master’s degree in Economics, statistics and econometrics from the University of Paris 1-Sorbonne (1990).

24) **Name:** Priti Patnaik  
**Title and affiliation:** Independent journalist and researcher  
**Location:** Morges, Switzerland

**Biography:** Priti Patnaik is a Geneva-based independent journalist and researcher reporting on global health, international trade and investment disputes. She has also reported on matters relating to illicit financial flows and natural resource governance. Outside of journalism, Priti was a legal researcher at a trade law firm and has worked as a consultant to World Health Organization in Geneva. She has also worked in New Delhi and New York reporting on finance and economics. Her work has been published by The Wire (India), Swiss Public Broadcasting (CH), Bilan (CH), The Guardian (UK), MarketWatch (UK), Breaking Views (USA), The Bond Buyer (USA), Business Standard (India), The Economic Times (India), among others.

Priti has a master’s degree in Development Studies from The Graduate Institute in Geneva and a master’s in Business and Economic Reporting from New York University, USA. She has a Bachelor’s in Science in Microbiology, Genetics and Chemistry from Osmania University, India. In addition, she also has a Bachelor’s in Economics from B R Ambedkar Open University, India.

25) **Name:** Vincenzo Pavone
**Title and affiliation:** Director, Institute of Public Goods and Policies (IPP), Spanish National Research Council (CSIC)

**Location:** Madrid, Spain

**Biography:** With a background in political science and a master in politics and government, Vincenzo Pavone is a Doctor in Social and Political Science from the European University Institute (EUI) with a thesis on the impact of scientific humanism on the creation, developments and programmes of UNESCO. First lecturer in Politics and International Relations at the Mediterranean Centre for Arts and Sciences (MCAS), Siracusa (Italy), Vincenzo joined the Institute of Public Policies of the CSIC as a post-doctoral researcher in 2006.

At the IPP he has developed a research line in critical science and technology studies, with a special focus on the social and political implications of emerging technologies, such as surveillance-oriented security technologies, transgenics and cisgenics, as well as assisted reproductive technologies. Always working on the complex relationship between science, technology and politics, with a special focus on neoliberalism, Vincenzo has recently opened a new research line on the global bioeconomy.

26) **Name:** Mariângela Simão

**Title and affiliation:** Assistant Director General, Prequalification and Technology Assessment, World Health Organization (WHO)

**Location:** Geneva, Switzerland

**Biography:** Dr Mariângela Batista Galvão Simão from Brazil was most recently WHO Assistant Director-General for Drug Access, Vaccines and Pharmaceuticals. She was Director of Community Support, Social Justice and Inclusion at UNAIDS. In addition to her work at UNAIDS, she brings more than 30 years of experience working in the Brazilian public health system and has played an active role in enhancing access and decentralizing health services in the country.

Between 2006 and 2010, she served as Director of the National STD/AIDS and Viral Hepatitis Department in the Brazilian Ministry of Health, where she led successful price negotiations with pharmaceutical companies to lower the price of HIV medication. During this time, she also represented the Brazilian Ministry of Health in the negotiations that led to the constitution of UNITAID in 2006, including its governing body, where she served as a board member until 2008. She was trained as a paediatrician in Brazil and holds an MSc degree in public health from the University of London, United Kingdom.

27) **Name:** Diane Singhroy

**Title and affiliation:** Research Associate, McGill International TB Centre

**Location:** Montreal, Canada

**Biography:** Dr. Diane Singhroy is a Research Associate at the McGill International TB Centre. Previously Dr. Singhroy served as Scientific and Technical Advisor at Knowledge Ecology International (KEI). Prior to this, Diane worked as a graduate student researcher in
Dr. Mark Wainberg’s laboratory at the McGill AIDS centre studying drug resistant HIV and innate immune interactions.

Diane has worked on access to medicines issues for University Allied for Essential Medicine (UAEM) as a chair of the Trade group and member of the North American coordinating committee (cc). There she advocated on issues ranging from the TPP, the R&D Treaty and academic activism. In her final year at UAEM, she was a UAEM cc fellow and served on the global governance council. Before starting her PhD at McGill Diane worked for the Office of Clinical trials at Health Canada as a screening officer.

Diane holds a BSc in Health sciences (concentration in biochemistry and molecular biology) from Carleton University, Ottawa, and a PhD in Immunovirology from McGill University, Montreal.

28) **Name:** Richard Sullivan  
**Title and affiliation:** Director, Institute of Cancer Policy, King’s College, London  
**Location:** London, United Kingdom

**Biography:** Richard Sullivan is Professor, Cancer Policy & Global Health at Kings College London and Director of the new Kings Institute of Cancer Policy. As a member of the Integrated Cancer Centre executive he leads the international strategy and is also Visiting Professor at the Faculty of Medicine, Universidad Catolica, Chile, and Washington University. Richard also serves on Kings Centre for Global Health and the Marjan Centre for Conflict & Conservation.

Richard qualified in medicine at St. Marys Hospital, London. Following training in surgery (onco-urology) he undertook a PhD and post-doctoral research in cell signalling at University College London. He then worked in a senior role in the pharmaceutical industry before spending nearly a decade with one of the worlds biggest NGO funders of cancer R&D Cancer Research UK as their clinical director. There he led on a number of major strategies including developing and launching the UK’s Experimental Cancer Medicine Centres and the development of the European Comprehensive Cancer Centres program. In 2008 Richard moved back into research at the London School of Economics were he studied complex healthcare systems within the health, society and population programme having previously worked in conflict and post conflict public health settings in the Balkans, Africa and most recently Middle East. He serves on a wide variety of advisory boards, including Charite Comprehensive Cancer Centre Berlin, Irish Clinical Oncology Group, Pfizer Policy Advisory Board, et al. He is past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security think-tank where he specialised in counter-proliferation and the security implications of global health.

Richard’s research programmes extend from the public policy of global cancer, to the development of public health systems in high-risk, conflict areas focusing on DR Congo, Afghanistan & Libya. In cancer public policy he has led on a number of major Lancet Oncology Commissions examining the affordability of cancer in high-income countries, global childhood cancer care and f cancer systems in Latin America. He is also chief
investigator for a number of conflict and health programs including, analysis of the basic package of health services in Afghanistan, the post conflict reconstruction of Libya’s NCD system and the impact of the Syrian conflict on future population health, amongst others.

29) **Name:** Karin Timmermans  
**Title and affiliation:** Technical Manager, Strategy Team, Unitaid  
**Location:** Geneva, Switzerland  

**Biography:** Karin Timmermans is an expert in intellectual property and pharmaceutical supply & regulation. She came to Unitaid in 2011 after World Health Organization posts in Guinea, Indonesia, India and the Philippines. Before joining WHO she worked with a medicine-supply NGO in Uganda. Karin says her career has been guided by an abiding interest in the subject matter. “I enjoy the combination of the technical and the practical,” she says. “And I believe in what I do. I believe that everybody should have access to medicine and treatment.” Karin is from the Netherlands and holds master’s degrees in pharmaceutical sciences and political science.

30) **Name:** Marcel Van Raaij  
**Title and affiliation:** Director of Pharmaceutical Affairs and Medical Technology, Ministry of Health, Welfare, and Sports, Netherlands  
**Location:** The Hague, Netherlands  

**Biography:** Marcel van Raaij studied Medical Biology at the State University of Leiden (The Netherlands) and received his PhD in Physiology at the same university. After his PhD he moved to the field of toxicological risk assessment stationed at the National Institute of Public Health and Environment (RIVM). He was active in various international working groups and commissions (EU,WHO, OECD, US EPA) dealing with regulatory frameworks on e.g. pesticides, biocides and accidental exposures to (industrial) chemicals. After leading the Center for Integrated Risk Assessment for a number of years at RIVM, he became acting director for Nutrition, Medicines and Consumer Safety. From 2011 to 2014 he was Director of Environment and Safety at RIVM dealing with environmental policy and physical safety including preparedness and response activities.  

In October 2014 Marcel van Raaij was appointed as Director of Pharmaceutical Affairs and Medical Technology at the Ministry of Health in the Netherlands. The Directorate is responsible for the policy making on pharmaceuticals (from innovation, market access, safe use to pricing and reimbursement), medical devices and technology and tissues and cells including organ donation policy.

31) **Name:** Esther Van Zimmeren  
**Title and affiliation:** Research Professor in Intellectual Property (IP) Law & Governance, Faculty of Law, University of Antwerp
Location: Antwerp, Belgium

Biography: Esther van Zimmeren is Research Professor in Intellectual Property (IP) Law & Governance at the Faculty of Law of the University of Antwerp (2013-present). She is a member of the Research Groups Government & Law and Business & Law. Between 2015-2017 she was the Head of the Research Group Government & Law. She is also a member of the interdisciplinary Jean Monnet Centre of Excellence ACTORE (Antwerp Consortium on the Organization of Rulemaking and Multi-level Governance in Europe) (in collaboration with the Faculty of Social Sciences).

At the University of Antwerp, she is teaching intellectual property law and EU internal market law. She is also the coordinator for the Module Law & International Business and the new Module Diversity & Law of the English Master's Program of the Faculty of Law. Esther is Visiting Professor at the University of Copenhagen and the University of Vilnius. Together with Sigrid Pauwels she established the Metropolitan Legal Lab aimed at creating a forum for legal topics related to the Metropolitan City and to enable interdisciplinary debate and collaboration in this area.

She has two Master Degrees from the University of Tilburg (Master in Dutch law and Master in International and European Law), an LL.M. in EU & IP Law from the KU Leuven (2002) and a PhD in Law from the KU Leuven (2011).

She has particular expertise in IP law, in particular in patent law, IP governance, innovation policy, technology transfer, competition law, contract law, European institutional and economic law and international trade law.

32) Name: Robert Watson  
Title and affiliation: Founding Partner, Gyrus Capital  
Location: Geneva, Switzerland

Biography: Dr. Robert Watson is a Founding Partner at Gyrus Capital. Dr. Watson was most recently a Managing Director at Altaris Capital Partners, a leading healthcare-focused private equity firm based in New York, where he led the firm's investments in the pharma and life sciences sectors. He has broad experience investing across the healthcare and technology industries, in companies based in Europe, the US and in Asia. Prior to Altaris, he worked at HgCapital in London, Ares Life Sciences in Geneva, and Sofinnova Partners in Paris.

Before investing Dr. Watson was a neuroscientist and has published research into neurodegenerative diseases. He has an MBiochem in Biochemistry and a DPhil in Neurology from the University of Oxford.

33) Name: Polly Webster  
Title and affiliation: Senior Policy Advisor, Government Relations, Kaiser Permanente  
Location: Washington, DC, United States of America
Biography: Polly F. Webster is a senior policy adviser for Kaiser Foundation Health Plan in Washington, D.C., working on pharmacy and drug pricing and coverage policy and regulatory issues. She previously served as health policy director for Rep. Diana DeGette (D-CO) and staffed the Senate Committee on Finance.

34) Name: Ellen 't Hoen  
Title and affiliation: Director, Medicines Law & Policy  
Location: Amsterdam, Netherlands

Biography: Ellen 't Hoen, LLM PhD, is a lawyer and public health advocate with over 30 years of experience working on pharmaceutical and intellectual property policies.

From 1999 until 2009 she was the director of policy for Médecins sans Frontières' Campaign for Access to Essential Medicines. In 2009 she joined UNITAID in Geneva to set up the Medicines Patent Pool (MPP) She was the MPP’s first executive director until 2012. In 2005, 2006, 2010 and 2011 she was listed as one of the 50 most influential people in intellectual property by the journal Managing Intellectual Property. She has worked as an advisor to a number of governments, NGOs and international organisations. She is currently a researcher at the Global Health Unit of the University Medical Centre at the University of Groningen, The Netherlands.

She has published widely on medicines law and policy issues. Her latest book “Private Patents and Public Health: Changing intellectual property rules for public health” was published July 2016.

She has a Masters of Laws from the University of Amsterdam and a PhD from the University of Groningen.